PRESS RELEASE : Medios AG: Successful completion of the Cranach Pharma acquisition - Market position strengthened significantly

DGAP-News: Medios AG / Key word(s): Takeover/Expansion 
Medios AG: Successful completion of the Cranach Pharma acquisition - Market position strengthened significantly 
2021-01-21 / 16:20 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Press Release 
Medios AG: Successful completion of the Cranach Pharma acquisition - Market position strengthened significantly 
Berlin, 21 January 2021 - Today, Medios successfully completed the takeover of the specialized pharmaceutical 
wholesaler Cranach Pharma GmbH, Hamburg. With the entry of the capital increase in kind in the commercial register, all 
closing conditions have now been fulfilled, meaning that the acquisition is completed. The German Federal Cartel Office 
had already granted clearance on 21 December 2020. As a result, Medios is now the largest provider of Specialty Pharma 
solutions in Germany. 
Through the merger with Cranach Pharma GmbH, Medios' partner network has grown from around 330 to around 500 
specialized pharmacies. For the 2021 financial year, Medios expects, including the acquired Cranach Pharma GmbH, a 
significant increase in group sales to more than EUR1 billion. 
Matthias Gärtner, Chairman of the Executive Board and Chief Financial Officer of Medios AG: "We are pleased to add our 
long-standing partner, Cranach Pharma, to the Medios Group. The acquisition strengthens our position as a full-service 
provider of Specialty Pharma solutions and gives us the opportunity to leverage an even broader product offering, as 
well as synergies in purchasing, sales and logistics. Our goal is to grow both organically and inorganically. We are 
well prepared for further acquisitions." 
The seller of Cranach Pharma GmbH is BMSH GmbH, which already holds a stake in Medios. The purchase price was paid in 
the form of 4,180,000 new Medios shares, which were created from authorized capital within a capital increase against 
contribution in kind. This is approximately 20.6% of the Medios share capital, after implementation of the capital 
increase. The purchase price for Cranach Pharma thus amounts to roughly EUR120.8 million based on a share price of 
approximately EUR28.90 per share. As a result, the share capital of Medios AG has increased from EUR16,084,991 to 
EUR20,264,991. Existing shareholdings of shareholders are reduced accordingly, so that reporting thresholds may also be 
undercut and voting rights notifications may become necessary. The new shares are subject to staggered lock-up periods 
of up to 24 months. As part of the acquisition, Medios will provide Cranach Pharma with funding of approximately EUR30 
million to strengthen its working capital and finance further growth. 
=------------------ 
About Medios AG 
Medios AG is the leading provider of Specialty Pharma solutions in Germany. As a competence partner and expert, Medios 
covers all relevant aspects of the supply chain in this field: from pharmaceutical supply and the manufacture of 
patient-specific therapies to drug safety, including blistering. The focus is on optimal patient care via specialized 
pharmacies. 
Medios AG is Germany's first listed Specialty Pharma company and member of the SDAX selection index. The shares (ISIN: 
DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard). 
www.medios.ag 
Contact 
Claudia Nickolaus 
Head of Investor & Public Relations 
Medios AG 
Heidestraße 9 | 10557 Berlin | Germany 
P [phone] 
[e-mail] 
www.medios.ag 
Nikolaus Hammerschmidt 
Senior Consultant Investor & Public Relations 
Kirchhoff Consult AG 
Borselstraße 20 | 22765 Hamburg | Germany 
P [phone] 
[e-mail] 
www.kirchhoff.de 
Disclaimer 
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future 
results may significantly deviate from currently expected results, specifically due to various risk factors and 
uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, 
uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no 
responsibility whatsoever for updating the forward-looking statements contained in this notification. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-01-21 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Medios AG 
              Heidestraße 9 
              10557 Berlin 
              Germany 
Phone:        [phone] - 800 
Fax:          [phone] - 801 
E-mail:       [e-mail] 
Internet:     www.medios.ag 
ISIN:         DE000A1MMCC8 
WKN:          A1MMCC 
Indices:      SDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf 
EQS News ID:  1159262 
 
End of News   DGAP News Service 
=---------- 

(MORE TO FOLLOW) Dow Jones Newswires

January 21, 2021 10:21 ET (15:21 GMT)